AMENDMENTS TO THE CLAIMS:

This listing of the claims will replace all prior versions and listing of claims in this application.

1. (**Withdrawn**) A pharmaceutical composition for preventing or treating a Th1-mediated immune disease, which comprises as an active ingredient a substance capable of acting on the natriuretic peptide receptor guanylyl cyclase A to enhance the production of cyclic guanosine monophosphate in an amount effective to prevent or treat a Th1-mediated immune disease.

2. (**Withdrawn**) The pharmaceutical composition according to claim 1, wherein the Th1-mediated immune disease is a disease due to graft rejection following transplantation, graft-versus-host disease caused by bone marrow transplantation, or an autoimmune disease.

3. (**Withdrawn**) The pharmaceutical composition according to claim 2, wherein the autoimmune disease is autoimmune hepatitis, chronic rheumatoid arthritis, insulin-dependent diabetes mellitus, ulcerative colitis, Crohn's disease, multiple sclerosis, autoimmune myocarditis, psoriasis, scleroderma, myasthenia gravis, multiple myositis/dermatomyositis, Hashimoto's disease, autoimmune hypocytosis, pure red cell aplasia, aplastic anemia, Sjogren's syndrome, vasculitis syndrome, or systemic lupus erythematosus.

4. (**Withdrawn**) The pharmaceutical composition according to claim 3, wherein the autoimmune disease is Crohn's disease or multiple sclerosis.

5. (**Withdrawn**) The pharmaceutical composition according to claim 1, wherein the substance capable of acting on the natriuretic peptide receptor guanylyl cyclase A to enhance the production of cyclic guanosine monophosphate is a natriuretic peptide.

6. (**Withdrawn**) The pharmaceutical composition according to claim 5, wherein the natriuretic peptide is atrial natriuretic peptide or brain natriuretic peptide.

7. (**Withdrawn**) The pharmaceutical composition according to claim 6, wherein the atrial natriuretic peptide is of human origin.

8. (**Currently Amended**) A method for treating a Th1-mediated immune disease~~, which comprises administering a substance capable of acting on the natriuretic peptide receptor guanylyl cyclase A to enhance the production of cyclic guanosine monophosphate~~ comprising administering an atrial natriuretic peptide or brain natriuretic peptide, wherein said Th1-mediated immune disease is a disease due to graft rejection following transplantation or multiple sclerosis.

9. (**Currently Amended**) The method according to claim 8, wherein the Th1-mediated immune disease is ~~selected from~~ a disease due to graft rejection following transplantation~~, graft-versus-host disease caused by bone marrow transplantation, or an autoimmune disease~~.

10. (**Currently Amended**) The method according to claim [[9]] 8, wherein the Th1-mediated immune disease is ~~autoimmune disease is autoimmune hepatitis, chronic rheumatoid arthritis, insulin-dependent diabetes mellitus, ulcerative colitis, Crohn's disease,~~ multiple sclerosis~~, autoimmune myocarditis, psoriasis, scleroderma, myasthenia gravis, multiple myositis/dermatomyositis, Hashimoto's disease, autoimmune hypocytosis, pure red cell aplasia, aplastic anemia, Sjogren's syndrome, vasculitis syndrome, or systemic lupus erythematosus~~.

11. (**Cancelled**)

12. (**Cancelled**)

13. (**Cancelled**)

14. (**Currently Amended**) The method according to claim [[13]] 8, wherein the atrial natriuretic peptide is of human origin.

15. (**Withdrawn**) A method of manufacturing a pharmaceutical composition for preventing or treating a Th1-mediated immune disease comprising admixing a substance capable of acting on the natriuretic peptide receptor guanylyl cyclase A to enhance the production of cyclic guanosine monophosphate with a pharmacologically acceptable carrier, excipient or diluent.

16. (**Withdrawn**) The method according to claim 15, wherein the Th1-mediated immune disease is selected from a disease due to graft rejection following transplantation, graft-versus-host disease caused by bone marrow transplantation, or an autoimmune disease.

17. (**Withdrawn**) The method according to claim 16, wherein the autoimmune disease is autoimmune hepatitis, chronic rheumatoid arthritis, insulin-dependent diabetes mellitus, ulcerative colitis, Crohn's disease, multiple sclerosis, autoimmune myocarditis, psoriasis, scleroderma, myasthenia gravis, multiple myositis/dermatomyositis, Hashimoto's disease, autoimmune hypocytosis, pure red cell aplasia, aplastic anemia, Sjogren's syndrome, vasculitis syndrome, and systemic lupus erythematosus.

18. (**Withdrawn**) The method according to claim 17, wherein the autoimmune disease is Crohn's disease or multiple sclerosis.

19. (**Withdrawn**) The method according to claim 15, wherein the substance capable of acting on the natriuretic peptide receptor guanylyl cyclase A to enhance the production of cyclic guanosine monophosphate is a natriuretic peptide.

20. (**Withdrawn**) The method according to claim 19, wherein the natriuretic peptide is atrial natriuretic peptide or brain natriuretic peptide.

21. (**Withdrawn**) The method according to claim 20, wherein the atrial natriuretic peptide is of human origin.

22. (**Currently Amended**) A method for regulating the Th1/Th2 balance in the immune system~~,~~ ~~which comprises~~ comprising treating dendritic cells with an ~~substance capable of acting on the natriuretic peptide receptor guanylyl cyclase A to enhance the production of cyclic guanosine monophosphate~~ atrial natriuretic peptide or brain natriuretic peptide, [[and]] thereby polarizing T cells toward Th2-promoting phenotype.

23. (**Cancelled**)

24. (**Cancelled**)

25. (**Currently Amended**) The method according to claim [[24]] 22, wherein the atrial natriuretic peptide or brain natriuretic peptide is of human origin.